Phase I escalation study of clofarabine (Clolar) and liposomal daunorubicin (DaunoXome) in childhood and adolescent acute myeloid leukaemia.

Trial Profile

Phase I escalation study of clofarabine (Clolar) and liposomal daunorubicin (DaunoXome) in childhood and adolescent acute myeloid leukaemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs Clofarabine (Primary) ; Daunorubicin liposomal
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Acronyms CLOUD
  • Most Recent Events

    • 01 Dec 2012 Accrual to date is 72% according to United Kingdom Clinical Research Network record.
    • 27 Jul 2011 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 27 Jul 2011 Actual end date (30 Jun 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top